Effects of AZP-531, a First-in-Class Unacylated Ghrelin Analog, on Food-Related Behaviour in Prader-Willi Patients: A Multi-Center, Randomized, Placebo-Controlled Study
aAlizé Pharma, Ecully, France; bEndocrinology and Nutrition Department, Sabadell University Hospital, Corporació Sanitària Parc Taulí, Research Institute I3PT, Sabadell, Spain; cNutrition Department, Institute of cardiometabolism and Nutrition, Pitié-Salpêtrière Hospital, Paris, France; dMarin Hospital, Hendaye, France; eRangueil Hospital, Toulouse, France; fDepartment of Endocrinology, Bone Diseases, Genetics, and Gynaecology, Childrens Hospital, Toulouse, France; gAutoimmune Endocrine Diseases Unit, Bambino Gesù, Research Hospital, Palidoro, Rome, Italy; hDepartment of Endocrinology, Diabetes and Nutrition, Angers Hospital, Angers, France; iDivision of Auxology, Istituto Auxologico Italiano, Piancavallo, Verbania, Italy
hrp0086fc13.5